menu
    • menu

    Company profile for Ascidian Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ascidian Therapeutics is a biotechnology company that specializes in treating human diseases through RNA rewriting. The company's therapeutic approach involves editing exons at the RNA level, allowing for precise post-transcriptional editing of genes. This editing process aims to produce full-length, functional proteins at optimal levels, within the right cells, and at the appropriate times. Ascidian Therapeutics is actively e...
    Ascidian Therapeutics is a biotechnology company that specializes in treating human diseases through RNA rewriting. The company's therapeutic approach involves editing exons at the RNA level, allowing for precise post-transcriptional editing of genes. This editing process aims to produce full-length, functional proteins at optimal levels, within the right cells, and at the appropriate times. Ascidian Therapeutics is actively engaged in discovery and preclinical programs focused on a range of conditions, including retinal diseases, neurological disorders, neuromuscular conditions, and genetically defined diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ascidian TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    80 GUEST STREET FOURTH FLOOR BOSTON MA 02135
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ascidian-tx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ascidian-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/AscidianTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascidian Names Abramson CDO, Forms Eye Advisory Board
    Ascidian Names Abramson CDO, Forms Eye Advisory Board

    24 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascidian-therapeutics-appoints-dr-murray-a-abramson-as-chief-development-officer-and-establishes-ophthalmology-clinical-advisory-board-to-advance-acdn-01-for-treatment-of-stargardt-disease-302488604.html

    PR NEWSWIRE
    24 Jun 2025
    Share Share
    Roche partners with Ascidian Therapeutics to develop gene therapies
    Roche partners with Ascidian Therapeutics to develop gene therapies

    19 Jun 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/roche-partners-with-ascidian-therapeutics-develop-gene-therapies-2024-06-18/

    REUTERS
    19 Jun 2024
    Share Share
    Ascidian Therapeutics Announces First-Ever IND for an RNA Exon Editor as FDA Approves Trial Plan and Fast Tracks ACDN-01 in Stargardt Disease and Other ABCA4 Retinopathies
    Ascidian Therapeutics Announces First-Ever IND for an RNA Exon Editor as FDA Approves Trial Plan and Fast Tracks ACDN-01 in Stargardt Disease and Other ABCA4 Retinopathies

    29 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascidian-therapeutics-announces-first-ever-ind-for-an-rna-exon-editor-as-fda-approves-trial-plan-and-fast-tracks-acdn-01-in-stargardt-disease-and-other-abca4-retinopathies-302046287.html

    PR NEWSWIRE
    29 Jan 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search